This article explores the landscape of undervalued US biotech stocks, identifying companies with promising pipelines and market positions poised for over 15% growth by Q3 2025, offering strategic insights for investors.

This analysis delves into the impact of FDA Fast-Track designations on biotech stock performance over the past five years in the US market. It examines how these designations influence investor sentiment and market valuation.